Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07407686

Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services

Earlier work explored barriers and facilitators to accessing prostate cancer screening, particularly in underserved communities, and provided valuable insights to build upon.

This study will explore perspectives on how genetic risk for prostate cancer is explained and understood through in-depth interviews with members of underserved communities. Findings from this work, alongside earlier results, will be used to co-design clear and accessible digital educational resources in collaboration with community members and relevant charities.

Participation in cancer screening programmes in the UK varies, with differences linked to socioeconomic status, ethnicity and health literacy. Similar inequalities are seen in access to prostate cancer genetics services, indicating a need for improved engagement.

Successful integration of genetics into prostate cancer care requires clear and inclusive information about genetic testing processes, possible outcomes and interpretation of results. Currently, there are limited resources explaining genetic risk for prostate cancer in an accessible way.

Co-production with representatives from underserved communities will ensure that educational materials are understandable, relevant and acceptable to all.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

About this study

There is variability in uptake of cancer screening programmes in the UK with participation affected by socioeconomic status, ethnicity & health literacy. This lack of representation is also seen within the prostate cancer genetics service, suggesting that further work is required to promote engagement. The successful mainstream integration of genetics into prostate cancer management will require people to understand the process, potential outcomes and interpretation of results. In addition, the information provided should be inclusive.

The barriers and facilitators to accessing prostate cancer screening work commenced under a service evaluation (CCR SE1284). This project provided valuable data from underserved communities which we wish to build on. This study aims to further explore perspectives on genetic risk explanation and education in further depth using semi-structured interviews and to use these and earlier findings to co-design educational digital materials to raise awareness about prostate cancer and genetic risk measurement, in keeping with the wishes from the communities that have worked with us.

Development of educational multi-media materials:

Utilising the Medical Research Council's Complex Intervention Design Framework, we will co-design educational materials, using the data collected from community champions and relevant charities.

Evaluation of educational multi-media materials:

The co-designed education materials will undergo evaluation in a pilot phase and then again after dissemination. Methods of evaluation will be adopted to include acceptability, usability and integration into clinical practice.

There are few current resources explaining the genetic risk of prostate cancer and opportunities to participate in genetic risk studies. The study will work alongside representatives from underserved communities to ensure that educational materials developed are accessible and acceptable to all.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and people with prostates age 18 and above
  • Those who belong to the three underserved groups; Black African and Black Caribbean Ancestry, transgender and non-binary people with a prostate and those with reduced access to healthcare
  • We allow intersectionality within reason and will narratively describe any instances of these in the writeup of findings
  • Those who are able to freely consent to inclusion
  • Individuals with and without a lived experience of prostate cancer

Exclusion criteria

  • To avoid exhaustion, we will only allow participation in two interview or focus groups per individual for the entirety of the study
  • Those without capacity to consent to interview (capacity is assumed unless there is good reason to believe otherwise)

Treatment and study plan

Surveys

Other

Up to 30 surveys with 10 of these individuals undergoing short interviews to assess the improvement of their understanding around prostate cancer

Semi-structured interviews and focus groups

Other

Up to 60 total semi-structured interviews (up to 20 per underserved group) to assess barriers and facilitators to prostate cancer screening and how they would like information to improve their understanding to be presented.

Primary outcomes

  1. Evaluation of educational materials, demonstrating that users have an increase in understanding or prostate cancer risk and symptoms as well as genetic risk.

    Time frame: February 2026 to August 2026

    Using surveys (before and after use of resources) and interviews to measure improvement in understanding in individuals without experience of prostate cancer.

  2. Increased representation from underserved groups in the referrals to our genetic research studies.

    Time frame: As soon as the educational materials are live, which we aim to be from June 2026, increase in referrals to our genetic research studies from under-represented groups will be measured. This will take place for 12 months.

    Using demographic data from referrals via our website to our genetic research studies

  3. Qualitative data such as hits to the webpage and scroll depth and how many have signed up to the genetic research studies via the website.

    Time frame: These data will be collected from as soon as the webpage goes live for the subsequent 12 months.

    This is a short term measure of how effective and engaging the resources are.

Secondary outcomes

  1. Improved representation of underrepresented groups in our genetic risk studies.

    Time frame: Measurements of the demographics of our research participants takes place currently. Any signficant change in representation will be reported for a minimum 12 months after the webpage and resources go live.

    Recruits to our genetic research studies will be screened for demographics.

  2. Reduced barriers to prostate cancer screening and participation in genetic research faced by underrepresented communities

    Time frame: The web page will go live in July 2026 and will be a long term resource (many years), regularly updated by our team. There will also be rounds of evaluation, using surveys and interviews, with subsequent adaption.

    These resources will be distributed by the community champions who we have co-designed them with. These community champions have social media networks with a strong following in their respective community and they are trusted by community members. Therefore, the resources and the webpage will have a far reach within the community to encourage engagement with empowering information and to promote prostate cancer screening and participation with our genetic risk studies.

Study contacts

Contact information is provided by the study sponsor or research team.

Elizabeth Bancroft

CONTACT

[email protected]

Rose Hall, MMBS

CONTACT

[email protected]

0000000000000000

Sponsors and collaborators

Lead sponsor

Royal Marsden NHS Foundation Trust

Other

Registry information

Official study title

Improving the Engagement of Underserved Communities With the Prostate Cancer Genetics Service: Identifying Barriers & Facilitators and Developing Supportive Resources Using a Co-production and Collaborative Approach

Acronym: INCLUDE PC

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Feb 12, 2026
Registry last updated
Feb 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.